Ironwood Pharmaceuticals (IRWD)
Develops gastrointestinal therapies around LINZESS and apraglutide.
$4.53
After-hours close0.00 (0.00%)
At close$4.53(+2.72%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114 | 118 | 75 | 94 | 92 | 91 | 41 | 85 | 122 | 48 | 107 | 113 |
| Cost of revenue | 1 | 0 | 26 | 0 | 30 | 0 | 27 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 113 | 118 | 49 | 94 | 62 | 91 | 14 | 85 | 122 | 48 | 106 | 113 |
| 65 | 80 | 38 | 69 | 36 | 59 | 43 | 40 | 44 | 41 | 34 | 34 | |
| Research & development | 32 | 36 | 26 | 30 | 30 | 25 | 27 | 23 | 22 | 22 | 21 | 22 |
| 32 | 39 | 0 | 37 | 36 | 34 | 0 | 17 | 22 | 19 | 12 | 11 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Other expenses | 0 | 6 | 12 | 2 | −30 | 0 | 15 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 49 | 38 | 11 | 25 | 26 | 31 | −29 | 45 | 78 | 7 | 73 | 79 |
| −17 | −7 | −6 | −6 | −8 | −7 | −7 | −7 | −10 | −6 | −7 | −6 | |
| Interest income | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Interest expense | 10 | 8 | 7 | 7 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 7 |
| Other non-operating income | 7 | −2 | 0 | −1 | −1 | −1 | −19 | −1 | 1 | −2 | −2 | −2 |
| Income before tax | 32 | 30 | 5 | 19 | 17 | 24 | −36 | 38 | 68 | 0 | 65 | 74 |
| Income tax expense | 18 | 32 | 9 | 20 | 14 | 22 | 1 | 14 | 28 | 3 | 24 | 22 |
| Net income from continuing operations | 14 | −2 | −4 | −1 | 4 | 2 | −37 | 24 | 40 | −2 | 41 | 51 |
| Net income | 15 | −1 | −4 | −1 | 4 | 2 | −37 | 24 | 40 | −2 | 41 | 51 |
| EPS, basic | $0.10 | −$0.01 | −$0.03 | −$0.01 | $0.02 | $0.01 | −$0.23 | $0.15 | $0.25 | −$0.01 | $0.25 | $0.31 |
| EPS, diluted | $0.08 | −$0.01 | −$0.03 | −$0.01 | $0.02 | $0.01 | −$0.23 | $0.14 | $0.23 | −$0.01 | $0.24 | $0.31 |
| Weighted average shares, basic | 156 | 156 | 158 | 159 | 160 | 160 | 161 | 162 | 162 | 162 | 163 | 165 |
| Weighted average shares, diluted | 187 | 156 | 158 | 159 | 160 | 160 | 161 | 162 | 178 | 178 | 167 | 165 |
| EBITDA | 42 | 41 | 12 | 27 | 27 | 33 | −10 | 47 | 77 | 9 | 75 | 81 |
| Depreciation & amortization | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 42 | 40 | 11 | 26 | 27 | 33 | −11 | 46 | 76 | 8 | 74 | 81 |